Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study

Patients receiving cytotoxic therapy for solid tumours are at risk of severe influenza. However, few data are available regarding the immunogenical efficacy of influenza vaccine in these patients. In this prospective study, 25 patients with breast (n=13) or prostate (n=12) cancer received a trivalen...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2011-05, Vol.104 (11), p.1670-1674
Main Authors: LOULERGUE, P, ALEXANDRE, J, LEBON, P, LAUNAY, O, LURISCI, I, GRABAR, S, MEDIONI, J, ROPERT, S, DIERAS, V, LE CHEVALIER, F, OUDARD, S, GOLDWASSER, F
Format: Article
Language:English
Subjects:
Adult
Age
Aged
Aged, 80 and over
Antibodies
Antibodies, Viral - biosynthesis
Antineoplastic Agents - therapeutic use
Betainfluenzavirus - immunology
Biological and medical sciences
Cancer
Clinical Study
Cytotoxicity
Data processing
Docetaxel
Female
Hemagglutination, Viral
Hemagglutinins
Human viral diseases
Humans
Immune response
Immunogenicity
Infectious diseases
Influenza
Influenza A Virus, H1N1 Subtype - immunology
Influenza Vaccines - adverse effects
Influenza Vaccines - immunology
Influenza virus
Male
Medical sciences
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Pilot Projects
Prostate
Prostate cancer
Seasonal variations
Seroconversion
Side effects
Sulfur dioxide
Taxoids - administration & dosage
Taxoids - therapeutic use
taxotere
Tumors
Vaccines
Viral diseases
Viral diseases of the respiratory system and ent viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients receiving cytotoxic therapy for solid tumours are at risk of severe influenza. However, few data are available regarding the immunogenical efficacy of influenza vaccine in these patients. In this prospective study, 25 patients with breast (n=13) or prostate (n=12) cancer received a trivalent inactivated influenza vaccine along with docetaxel (Taxotere) administration. The influenza virus type A and B antibody titres were measured using haemagglutinin inhibition (Garten et al, 2009) before and 21 days after the vaccination. Seroconversion rate was defined as the percentage of patients with an increase in the serum titres ≥ 4 after vaccination. Median age was 65 years (range: 33-87 years); 52% were females. Seroconversion rates were low: 28% (95% CI: 23.1-33.3) for H1N1, 8% (95% CI: 7.7-8.3) for H3N2 and 16% (95% CI: 7.7-25) for the B strain. The geometric mean titres ratios were 2.16 (H1N1), 1.3 (H3N2) and 1.58 (B). No serious adverse event (AE) related to the vaccine was reported. All the reported AE were from mild-to-moderate intensity. In the patients receiving docetaxel for solid tumours, influenza vaccine triggers an immune response in only one third. Strategies using more immunogenic influenza vaccines must be evaluated in such patients.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2011.142